Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00318708 · ClinicalTrials.gov registry record · Phase 3
Asthma Clinical Research Network (ACRN) Trial - Macrolides in Asthma (MIA)
A Phase 3 study of Asthma, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 92
- Enrollment target
- 10
- Study locations
NCT00318708: Completed Phase 3 study of Asthma, sponsored by Milton S. Hershey Medical Center.
NCT00318708 is a Phase 3 study of Asthma that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 92 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (94% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00318708, a Phase 3 study of Asthma, has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 92 participants
- Enrollment target
- 10
- Study locations
Study Summary
Asthma can be caused by a variety of factors, including tobacco smoke, allergens, and respiratory airway infections. Many people use inhaled corticosteroid medications to treat their symptoms. These medications, however, are not effective for everyone. Clarithromycin is an antibiotic that may effectively treat asthma in these individuals. This study will evaluate the effectiveness of clarithromycin at controlling asthma symptoms.
Primary Outcome
The Juniper asthma control questionnaire (ACQ) consists of six questions answered by the asthma patient with respect to symptoms, rescue medication use, and night-time awakenings due to asthma. A seventh item in the ACQ is the percent predicted FEV1. Each of the seven items is scored from from 0 (best) to 6 (worst), and then the seven items are averaged to yield a number from 0 (best) to 6 (worst). Asthma patients needed to display an ACQ greater than or equal to 1.25 in order to be eligible for
Conditions Studied
Interventions
- DRUG fluticasone propionate
- DRUG clarithromycin
- DRUG placebo clarithromycin
Study Locations (10)
California
- University of California, San Diego - San Diego
- University of California, San Francisco - San Francisco
North Carolina
- Duke University Medical Center - Durham
- Wake Forest University Health Sciences - Winston-Salem
Colorado
- National Jewish Medical and Research Center - Denver
Massachusetts
- Brigham & Women's Hospital - Boston
Missouri
- Washington University, St. Louis - St Louis
New York
- Columbia University Medical Center - New York
Texas
- University of Texas Medical Branch - Galveston
Wisconsin
- University of Wisconsin, Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2006-06 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
What the finished NCT00318708 record still lists
NCT00318708 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 3 interventions - of which fluticasone propionate is the first listed.
NCT00318708 lists 10 locations in 8 states (California, North Carolina, Colorado).
Frequently Asked Questions
What is clinical trial NCT00318708 about?
NCT00318708 is a clinical study titled "Asthma Clinical Research Network (ACRN) Trial - Macrolides in Asthma (MIA)". Asthma can be caused by a variety of factors, including tobacco smoke, allergens, and respiratory airway infections. Many people use inhaled corticosteroid medications to treat their symptoms. These medications, however, are not effective for everyone. Clarithromycin is an antibiotic that may effect...
What is the current status of trial NCT00318708?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 92 participants. The study started on 2006-06. Estimated completion is 2009-04.
What conditions does trial NCT00318708 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00318708?
The interventions under investigation include: fluticasone propionate (DRUG), clarithromycin (DRUG), placebo clarithromycin (DRUG).
Who is sponsoring clinical trial NCT00318708?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00318708 being conducted?
This trial has 10 study locations across California, Colorado, Massachusetts, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00318708's enrollment target sits among peer trials
92 220th of 374 higher than 155 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia